An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer

Biochimie ◽

10.1016/j.biochi.2015.03.003 ◽

2015 ◽

Vol 112 ◽

pp. 111-120 ◽

Author(s):

Xinghao Ai ◽

Shengping Shen ◽

Lan Shen ◽

Shun Lu

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Molecule ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Interaction Map ◽

Download Full-text

P1.03-010 Efficacy and Safety of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.814 ◽

2017 ◽

Vol 12 (11) ◽

pp. S1954

Author(s):

R. Imase ◽

S. Endo ◽

Y. Sasahara ◽

T. Shinmura ◽

T. Ozawa ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Download Full-text

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Line Treatment ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

Annals of Oncology ◽

10.1016/s0923-7534(20)32041-x ◽

2012 ◽

Vol 23 ◽

pp. xi44

Author(s):

P.-C. Yang ◽

R. Salgia ◽

B. Solomon ◽

A.T. Shaw ◽

D.R. Camidge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Visual Effects ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

Value in Health ◽

10.1016/j.jval.2020.08.244 ◽

2020 ◽

Vol 23 ◽

pp. S442

Author(s):

G. Gourzoulidis ◽

O. Zisimopoulou ◽

N. Boubouchairopoulou ◽

C. Michailidi ◽

C. Almond ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Previously Treated

Download Full-text

Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK -Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.11.015 ◽

2017 ◽

Vol 18 (4) ◽

pp. e251-e258 ◽

Author(s):

Tetsuhiko Asao ◽

Yutaka Fujiwara ◽

Kota Itahashi ◽

Shinsuke Kitahara ◽

Yasushi Goto ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Retrospective Analysis ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Japanese Patients ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

PD2.04 Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.09.131 ◽

2019 ◽

Vol 14 (11) ◽

pp. S1171-S1172

Author(s):

T. Leal ◽

H. Wakelee ◽

K.L. Reckamp ◽

A. Chiappori ◽

G.R. Oxnard ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Download Full-text

Four lines of anaplastic lymphoma kinase inhibitors and brain radiotherapy in a long-surviving non-small-cell lung cancer anaplastic lymphoma kinase-positive patient with leptomeningeal carcinomatosis

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000699 ◽

2019 ◽

Vol 30 (2) ◽

pp. 201-204 ◽

Author(s):

Concetta E. Onesti ◽

Daniela Iacono ◽

Silvia Angelini ◽

Marco Mazzotta ◽

Raffaele Giusti ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Leptomeningeal Carcinomatosis ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Brain Radiotherapy

Download Full-text

Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2020.1738387 ◽

2020 ◽

Vol 21 (8) ◽

pp. 931-940 ◽

Author(s):

Alice Indini ◽

Erika Rijavec ◽

Michele Ghidini ◽

Claudia Bareggi ◽

Donatella Gambini ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitors ◽

Small Cell Lung ◽

Anaplastic Lymphoma

Download Full-text

369 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72076-0 ◽

2010 ◽

Vol 8 (7) ◽

pp. 117 ◽

Author(s):

B. Solomon ◽

Y.J. Bang ◽

D.R. Camidge ◽

A.J. Iafrate ◽

E.L. Kwak ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Download Full-text

ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdw383.89 ◽

2016 ◽

Vol 27 ◽

pp. vi448 ◽

Author(s):

S. Popat ◽

M. Tiseo ◽

S. Gettinger ◽

S. Peters ◽

J. Haney ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Kinase Inhibitor ◽

Small Cell Lung ◽

Phase 3 ◽

Cancer Trial ◽

Anaplastic Lymphoma ◽

Download Full-text